CBR3 Antibody [DyLight 594]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-00346DL594
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA
Label
DyLight 594 (Excitation = 593 nm, Emission = 618 nm)
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for CBR3 Antibody [DyLight 594]
Immunogen
Produced in rabbits immunized with purified, recombinant Human CBR3 (Accession#: O75828; Met1-Trp277)
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for CBR3 Antibody [DyLight 594]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen and protein A Affinity-purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CBR3
Alternate Names
carbonyl reductase (NADPH) 3, carbonyl reductase (NADPH) 3, EC 1.1.1.18410EC 1.1.1, carbonyl reductase [NADPH] 3, carbonyl reductase 3, EC 1.1.1.184, hCBR3, NADPH-dependent carbonyl reductase 3, SDR21C2, short chain dehydrogenase/reductase family 21C, member 2
Gene Symbol
CBR3
Additional CBR3 Products
Product Documents for CBR3 Antibody [DyLight 594]
Product Specific Notices for CBR3 Antibody [DyLight 594]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...